Altimmune Inc (ALT)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Altimmune Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 2.80 $ — 6% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year -100.0% failed
- Share count grows by less than 3% a year 23.4% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -164,641.3% failed
- Gross margin at 40% or higher and without meaningful erosion 100.0% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 238 m net cash passed
- Operating cash flow covers the profits of the last three years 48 m failed
- Return on capital at 15% or higher, or up versus two years ago -35.7% failed
- Insiders hold at least 10% or are net buyers 0.4% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 515.0% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 9
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.57 | -0.63 – -0.52 | 0 | 42.7% | 6 |
| 12/31/2027 | -0.69 | -0.82 – -0.56 | 0 | -20.6% | 6 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.15 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.33 | – | 0 | -86.50 | -463,600.00 | -18 | -18 |
| 2025: Q1 | -0.26 | – | 0 | 0.00 | -391,500.00 | -17 | -17 |
| 2025: Q2 | -0.27 | – | 0 | 0.00 | -442,920.00 | -20 | -20 |
| 2025: Q3 | -0.21 | – | 0 | 0.00 | -380,280.00 | -12 | -12 |
| 2025: Q4 | -0.27 | – | 0 | 420.00 | -105,223.10 | -19 | -19 |
| 2026: Q1 | -0.18 | – | 0 | -100.00 | – | -21 | -21 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 5 | -11 | 194 | 841.45 | 202 | 19 | 225 |
| 2017 | 0 | -52 | -46 | -108.77 | -20 | 49 | 63 |
| 2018 | 10 | -43 | -39 | -13.98 | -9 | 48 | 55 |
| 2019 | 6 | -21 | -21 | -1.56 | -10 | 46 | 54 |
| 2020 | 8 | -55 | -49 | -1.91 | -34 | 226 | 245 |
| 2021 | 4 | -97 | -97 | -2.35 | -78 | 199 | 219 |
| 2022 | 0 | -88 | -85 | -1.81 | -63 | 185 | 207 |
| 2023 | 0 | -96 | -88 | -1.66 | -76 | 194 | 211 |
| 2024 | 0 | -103 | -95 | -1.34 | -80 | 124 | 139 |
| 2025 | 0 | -94 | -88 | -1.00 | -68 | 225 | 280 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Altimmune, Inc. , a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.
| Employees | 57 |
|---|---|
| Headquarters | Gaithersburg, MD |
| Address | 910 Clopper Road, 20878 Gaithersburg, United States |
| Phone | 240 654 1450 |
| Website | altimmune.com |
| IPO Date | 6. Oct 2005 |
| ISIN | US02155H2004 |
| Stock Split | 1:30 on 09/14/2018 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jerome Benedict Durso | Chairman, CEO & President | 1968 |
| M. Scot Roberts Ph.D. | Chief Scientific Officer | 1959 |
| Christophe Arbet-Engels M.B.A., M.D., Ph.D. | Chief Medical Officer | 1963 |
| Gregory L. Weaver CPA, M.B.A. | Chief Financial Officer | 1956 |
| Andrew Shutterly M.S. | Principal Financial & Accounting Officer and Corporate Controller | 1988 |
| Bertrand Georges Ph.D. | Chief Technology Officer | – |
| Tony Blandin B.S. | Vice President of Quality & Compliance Management | – |
| Robin E. Abrams J.D. | Chief Legal Officer & Corporate Secretary | 1964 |
| Raymond M. Jordt M.B.A., M.S. | Chief Business Officer | 1973 |
| Linda M. Richardson | Chief Commercial Officer | 1964 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.